Vaxcyte Reports First Quarter 2023 Financial Results and Pro

08.05.2023 - - Positive Data from VAX-24 Phase 2 Study in Adults Aged 65 and Older Demonstrated Robust Immune Responses Across all 24 Serotypes (ST) at all Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64 - - Full Six-Month Safety Data from Both ...

Related Keywords

Andrew Guggenhime , Jennifer Zibuda , Janet Graesser , Exchange Commission , Groupa Strep , Sutro Biopharma Inc , Corporate Communications , Vaxcyte Inc , Adult Program , Nasdaq , Research Development Rd Expenses , Us Food Drug Administration , First Participants , Infant Phase , Invasive Pneumococcal Disease , Adult Investigational New Drug , Application Submission , Subsequent Clearance Announcement Expected , Second Half , Topline Phase , Cash Equivalents , Excluding Net Proceeds , Recent Public , Grant Pickering , Chief Executive Officer , Financial Officer , First Quarter , Positive Data , Adults Aged , Full Six Month Safety Data , Adult Phase , Older Results , Tolerability Findings , Both Adult Studies , Prespecified Pooled Analyses , Follow On Financing , Breakthrough Therapy Designation , Breakthrough Therapy , Sutro Biopharma , Private Securities Litigation Reform Act , Quarterly Report , Senior Director , Vice President , Months Ended March , Vaxcyte ,